Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Theravance Biopharma, Inc. (NASDAQ: TBPH).

Full DD Report for TBPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: TBPH)

Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
DUBLIN , May 17, 2018 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension (nOH) beginning at 12:00 p.m. ET on Thursday , May 24, 2018 in New York City . The event wil...
Source: PR Newswire
Date: May, 17 2018 08:30
Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Source: SeekingAlpha
Date: May, 15 2018 10:33
Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
DUBLIN , May 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2018 , ...
Source: PR Newswire
Date: May, 10 2018 08:30
Theravance Biopharma, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 08 2018 22:45
Theravance Biopharma's (TBPH) CEO Rick Winningham on Q1 2018 Results - Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q1 2018 Earnings Conference Call May 8, 2018 5:00 PM ET Executives Alex Dobbin – Head-Investor Relations Rick Winningham – Chief Executive Officer Brett Haumann – Chief Medical Officer Renée Galá – Chief Fi...
Source: SeekingAlpha
Date: May, 08 2018 22:40
Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
DUBLIN , May 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter ended March 31, 2018 . Revenue for the first quarter of 2018 was $8.3 million . The Company's first quarter ope...
Source: PR Newswire
Date: May, 08 2018 16:05
Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018
DUBLIN , May 1, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2018 and provide a business update after market close on Tuesday, May 8, 2018 ....
Source: PR Newswire
Date: May, 01 2018 16:05
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
DUBLIN , April 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today highlighted that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta. This expanded approval in the US allows Trelegy Ellipta...
Source: PR Newswire
Date: April, 25 2018 08:30
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
DUBLIN , April 23, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV ® (telavancin) were presented at the 28th European Congress of Clinical Microbiology an...
Source: PR Newswire
Date: April, 23 2018 07:30
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious ...
Source: PR Newswire
Date: April, 20 2018 10:17

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1724.3824.4824.7623.94152,367
2017-02-0330.5330.88531.0429.87548,307
2017-02-0229.7330.3030.7029.555151,670
2017-02-0130.0529.9130.09528.79284,467
2017-01-3128.0529.9630.1927.80457,688

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2132,753150,50821.7616Cover
2018-08-2017,07938,19144.7200Short
2018-08-178,22025,66432.0293Cover
2018-08-1618,12239,97745.3311Short
2018-08-1526,32045,41357.9570Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TBPH.


About Theravance Biopharma, Inc. (NASDAQ: TBPH)

Logo for Theravance Biopharma, Inc. (NASDAQ: TBPH)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: TBPH)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 01 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 19 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 21 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 06 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 15 2018

       

       


      Daily Technical Chart for (NASDAQ: TBPH)

      Daily Technical Chart for (NASDAQ: TBPH)


      Stay tuned for daily updates and more on (NASDAQ: TBPH)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: TBPH)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TBPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of TBPH and does not buy, sell, or trade any shares of TBPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/